Numeral has announced the opening of Numeral Biotechnologies in South Africa, which is fully owned by the company.
The company continues to focus on biotechnology and is actively looking for acquisitions in this field.
This announcement is made in line with the Stock Exchange of Mauritius (SEM ) Listing Rules and the Securities Act of Mauritius, as well as the JSE Listings Requirements.
Numeral is listed on the SEM and also has a secondary listing on the Alternative Exchange of the JSE.
Numeric Biotech is a biopharmaceutical company fully dedicated to cure rare diseases in the field of age-relating diseases. In particular where chronic (neuro) inflammation is a root cause of the disease.
“Our experienced management team is developing first-in-class compounds to eliminate the surplus of senescent cells and to reduce pro-inflammatory cytokines such as IL-6.,” said the company.
“Through selectively targeting the foxo4-p53 axis in the nucleus of the senescent cell our compounds will have specific control over the functionality and numbers of regulatory T-cells ( Tregs).
“By reducing pro-inflammatory cytokines and increasing Tregs, the compounds have the potential to become the first-in class immunomodulators for the treatment of chronic inflammatory diseases.”
Stellenbosch-based Biotech startup Immobazyme has secured R24.5 million for global expansion of its innovative enzyme immobilization and precision fermentation platform. This funding, led by the University Technology Fund (UTF) and University of Stellenbosch Enterprises (USE), will enable Immobazyme to double its facility size and dramatically scale its high-value proteins and enzyme production capabilities.
The company plans to double the size of its facility and dramatically scale its production capabilities, positioning itself at the forefront of South Africa’s biotech industry.
Dominic Nicholas, CEO of Immobazyme, expressed his gratitude in achieving this milestone.
“We’re incredibly grateful to all our investors and partners for recognising the value and impact of our work. We are poised to tackle real-world challenges, delivering economic, social, and environmental benefits to the private sector through our technology. With this funding, we can now set our sights on bigger, more ambitious goals. Our immediate focus is on scaling our facility to introduce our products to the global market.”
